NO20084167L - Middel som oppviser nevrotropisk, nevromodulerende og cerebrovaskulaer aktivitet, samt aktivitet mot slag - Google Patents

Middel som oppviser nevrotropisk, nevromodulerende og cerebrovaskulaer aktivitet, samt aktivitet mot slag

Info

Publication number
NO20084167L
NO20084167L NO20084167A NO20084167A NO20084167L NO 20084167 L NO20084167 L NO 20084167L NO 20084167 A NO20084167 A NO 20084167A NO 20084167 A NO20084167 A NO 20084167A NO 20084167 L NO20084167 L NO 20084167L
Authority
NO
Norway
Prior art keywords
activity
neurotropic
cerebrovascular
neuromodulatory
well
Prior art date
Application number
NO20084167A
Other languages
English (en)
Norwegian (no)
Inventor
Valentina Ivanovna Akhapkina
Roman Vitalevich Akhapkin
Tatiana Aleksandrovna Voronina
Original Assignee
Valentina Ivanovna Akhapkina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentina Ivanovna Akhapkina filed Critical Valentina Ivanovna Akhapkina
Publication of NO20084167L publication Critical patent/NO20084167L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20084167A 2006-03-28 2008-10-03 Middel som oppviser nevrotropisk, nevromodulerende og cerebrovaskulaer aktivitet, samt aktivitet mot slag NO20084167L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006109678/15A RU2329804C2 (ru) 2006-03-28 2006-03-28 Вещество, обладающее нейротропной - нейромодуляторной активностью
PCT/RU2007/000094 WO2007111528A1 (fr) 2006-03-28 2007-02-27 Agent à activité neurotrope, neuromodulatrice, cérébrovasculaire et dirigée contre le acv

Publications (1)

Publication Number Publication Date
NO20084167L true NO20084167L (no) 2008-12-29

Family

ID=38541382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084167A NO20084167L (no) 2006-03-28 2008-10-03 Middel som oppviser nevrotropisk, nevromodulerende og cerebrovaskulaer aktivitet, samt aktivitet mot slag

Country Status (25)

Country Link
US (1) US20090291999A1 (uk)
EP (1) EP2011497B8 (uk)
JP (1) JP5241702B2 (uk)
KR (1) KR20080111111A (uk)
CN (1) CN101415418B (uk)
AT (1) ATE507829T1 (uk)
BR (1) BRPI0709230A2 (uk)
CA (1) CA2647512C (uk)
CY (1) CY1111732T1 (uk)
DE (1) DE602007014351D1 (uk)
DK (1) DK2011497T3 (uk)
EA (1) EA015469B1 (uk)
ES (1) ES2365426T3 (uk)
FI (1) FI20086017A (uk)
HR (1) HRP20110523T8 (uk)
ME (1) ME01227B (uk)
MX (1) MX2008012318A (uk)
NO (1) NO20084167L (uk)
PL (1) PL2011497T3 (uk)
PT (1) PT2011497E (uk)
RS (1) RS51827B (uk)
RU (1) RU2329804C2 (uk)
SI (1) SI2011497T1 (uk)
UA (1) UA92383C2 (uk)
WO (1) WO2007111528A1 (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
TW201408293A (zh) * 2012-07-05 2014-03-01 Merz Pharma Gmbh & Co Kgaa (r)-苯基披喇瑟盪於治療疾病相關疲勞之用途
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
WO2015184542A1 (en) * 2014-06-02 2015-12-10 Ketogen Inc. Compounds for the treatment of seizures and other central nervous system disorders and conditions
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2050851C1 (ru) 1990-08-28 1995-12-27 Институт медико-биологических проблем Вещество, проявляющее ноотропную активность
EA002380B1 (ru) 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Антиишемическое средство
RU2192585C2 (ru) * 2000-09-18 2002-11-10 Ивановский государственный энергетический университет Цоколь дымовой трубы
RU2183117C1 (ru) 2000-11-03 2002-06-10 Закрытое акционерное общество "АСГЛ-Исследовательские Лаборатории" Средство для нормализации артериального давления и способ лечения гипертонической болезни
RU2192858C1 (ru) * 2001-05-16 2002-11-20 Закрытое акционерное общество "АСГЛ-Исследовательские Лаборатории" Средство, обладающее антиишемической, гипотензивной и антигипоксической активностью
ATE404192T1 (de) * 2001-08-22 2008-08-15 Hamilton Pharmaceuticals Inc Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
RU2232578C1 (ru) 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
RU2240783C1 (ru) 2003-07-17 2004-11-27 Открытое акционерное общество "Щелковский витаминный завод" Фармацевтическая композиция, обладающая ноотропной активностью, и способ ее получения

Also Published As

Publication number Publication date
EP2011497B1 (en) 2011-05-04
KR20080111111A (ko) 2008-12-22
JP5241702B2 (ja) 2013-07-17
EA200801923A1 (ru) 2009-02-27
ES2365426T8 (es) 2013-12-26
ES2365426T3 (es) 2011-10-04
HRP20110523T1 (hr) 2011-08-31
FI20086017A (fi) 2008-10-28
EP2011497A4 (en) 2009-06-17
EA015469B1 (ru) 2011-08-30
WO2007111528A1 (fr) 2007-10-04
PT2011497E (pt) 2011-07-26
ATE507829T1 (de) 2011-05-15
SI2011497T1 (sl) 2011-09-30
EP2011497A1 (en) 2009-01-07
RU2329804C2 (ru) 2008-07-27
CA2647512A1 (en) 2007-10-04
CY1111732T1 (el) 2015-10-07
ME01227B (me) 2013-06-20
BRPI0709230A2 (pt) 2011-06-28
DK2011497T3 (da) 2011-08-15
HRP20110523T8 (en) 2014-01-31
US20090291999A1 (en) 2009-11-26
MX2008012318A (es) 2009-02-23
PL2011497T3 (pl) 2011-10-31
CN101415418B (zh) 2012-09-05
CA2647512C (en) 2013-06-25
CN101415418A (zh) 2009-04-22
EP2011497B8 (en) 2013-12-04
DE602007014351D1 (de) 2011-06-16
RU2006109678A (ru) 2007-10-10
UA92383C2 (uk) 2010-10-25
JP2009531423A (ja) 2009-09-03
RS51827B (en) 2012-02-29

Similar Documents

Publication Publication Date Title
NO20084167L (no) Middel som oppviser nevrotropisk, nevromodulerende og cerebrovaskulaer aktivitet, samt aktivitet mot slag
BR112013020517A2 (pt) dispositivo de segurança
UY30905A1 (es) Composiciones para mejorar la absorcion gastrointestinal de nutrientes y farmacos
MX2008000915A (es) Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.
WO2007038551A3 (en) Use of ibudilast for treating drug and behavioral addictions
ATE476446T1 (de) Acylierte glp-1 verbindungen
DK1909871T4 (da) Sprøjteanordning med en dosisbegrænsende mekanisme og en yderligere sikkerhedmekanisme
DE602006014691D1 (de) DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN
WO2010144721A3 (en) Model systems and treatment regimes for treatment of neurological disease
BRPI0507905A (pt) uso de compostos orgánicos
CY1110606T1 (el) Χρηση των ανταγωνιστων της il-23 και il-17 για τη θεραπεια της αυτοανοσης οφθαλμικης φλεγμονωδους νοσου
HN2010002786A (es) Compuestoa quimicos 251
ATE523491T1 (de) 3-heterocyclyl-3-hydroxy-2-amino-propionsäure- amide und damit zusammenhängende verbindungen mit analgesischer und/oder immunostimulatorischer aktivität
WO2007022089A3 (en) Methods to identify therapeutic agents useful for treating and preventing atherosclerosis by counteracting the effect of cholesterol ozonation products
WO2012170899A3 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
CY1112180T1 (el) 1-κεστοζη για θεραπεια αλλεργιας και ατοπικης δερματιτιδας
MX2008011454A (es) Uso novedoso de agentes antihistaminicos para el tratamiento preventivo o temprano de sindromes inflamatorios, en particular los que son accionados por togavirus.
GT200800235A (es) Formulacion de medicamento liquida
ATE390916T1 (de) Vorrichtung zur freisetzung von medikamenten
WO2008003013A3 (en) Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic
BRPI0601884A (pt) composição farmacêutica aplicável na terapêutica da doença de peyronie e respectivo processo de obtenção
EA200900603A1 (ru) Применение тимозин альфа-1 для получения лекарственного средства для профилактики и лечения аллергических реакций
Carr et al. Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13 (9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13 (3): 193-203
ES2472115R2 (es) Utilización de derivados bicíclicos de 1-desoxigalactonojirimicina en la preparación de un medicamento para el tratamiento de enfermedades relacionadas con beta-enzimas galactosidasas lisosómicas mutantes humanas
TH170136A (th) อินดาโซลคาร์บอกซาไมด์แบบใหม่ กระบวนการในการเตรียมสารดังกล่าว ยาเตรียม ทางเภสัชกรรมซึ่งประกอบรวมด้วยสารดังกล่าว และการใช้สารดังกล่าว ในการผลิตยารักษาโรค

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application